The information contained in these releases was current on the date the releases were issued and will become outdated over time. Lilly does not assume any responsibility for updating information in these releases.
Releases
 |
U.S. Court of Appeals Upholds Validity of Lilly's Evista Patents Through March of 2014
Sep 1, 2010
|
7.6 KB |
|
| |
INDIANAPOLIS, Sept 01, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company's method-of-use patents for Evista(R) (raloxifene HCl tablets) are v...
|
|
Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta(R) to a Broader Pain Population
Aug 19, 2010
|
11.6 KB |
|
| |
BETHESDA, Md., Aug 19, 2010 /PRNewswire via COMTEX News Network/ -- The U.S. Food and Drug Administration (FDA) Anesthetic and Life Support Drugs Advisory Committee voted today 8-6 in favor of expanding the pain indications for Eli Lilly and Company's (NYSE: LLY) Cymbalta(R) (duloxetine HCl) to a broader pain population that will be further defined...
|
|
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Aug 17, 2010
|
12.8 KB |
|
| |
INDIANAPOLIS, Aug 17, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long-term Phase III studies showed it did not slow disease progression an...
|
|
U.S. District Court Rules Against Lilly Regarding Strattera Patent
Aug 12, 2010
|
8.8 KB |
|
| |
INDIANAPOLIS, Aug 12, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. District Court for the District of New Jersey has ruled against the company in its patent litigation for Strattera(R) (atomoxetine). In the case of Eli Lilly and Company v. Actavis Elizabeth LLC, et al, the court ruled ...
|
|
The American Diabetes Association and Eli Lilly and Company Encourage African-Americans to Face the Music about Diabetes Management
Aug 5, 2010
|
13.0 KB |
|
| |
ATLANTA, Aug 05, 2010 /PRNewswire via COMTEX News Network/ -- The 12th annual Victory Over Diabetes event, hosted by the American Diabetes Association (the Association), will take place in Atlanta on August 7, featuring Eli Lilly and Company's Fearless African-Americans Connected and Empowered (F.A.C.E.) Diabetes initiative and campaign spokesperso...
|
|
U.S. Court of Appeals Rules on Validity of Lilly's Gemzar Method-of-Use Patent
Jul 28, 2010
|
8.0 KB |
|
| |
INDIANAPOLIS, July 28, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has upheld a prior ruling by the U.S. District Court for the Eastern District of Michigan that Gemzar's method-of-use patent is invalid.
"We strongly disagree with the ruling b...
|
|
Lilly Reports Strong Second-Quarter 2010 Results
Jul 22, 2010
|
155.0 KB |
|
| |
INDIANAPOLIS, July 22, 2010 /PRNewswire via COMTEX News Network/ -- Nine percent revenue growth driven by higher volume continues strong trend for the year.21 percent of Q2 revenue invested in R&D to advance pipeline of nearly 70 potential new medicines in clinical development.Ongoing cost-containment efforts support double-digit growth in operatin...
|
|
Lilly Announces Completion of Alnara Acquisition
Jul 20, 2010
|
7.8 KB |
|
| |
INDIANAPOLIS, July 20, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has completed the acquisition of Alnara Pharmaceuticals, Inc., a privately-held company developing protein therapeutics for the treatment of metabolic diseases. The transaction, first announced on July 2, 2010, has received ...
|
|
Lilly Confirms Date and Conference Call for Second-Quarter 2010 Financial Results Announcement
Jul 9, 2010
|
7.1 KB |
|
| |
INDIANAPOLIS, July 9, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2010 on Thursday, July 22, 2010. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
The...
|
|
Lilly to Acquire Alnara Pharmaceuticals
Jul 2, 2010
|
11.3 KB |
|
| |
INDIANAPOLIS and CAMBRIDGE, Mass., July 2, 2010 /PRNewswire via COMTEX News Network/ -- Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc. today announced they have signed a definitive merger agreement whereby Lilly will acquire Alnara, a privately held biotechnology company developing protein therapeutics for the treatment of metab...
|
|
Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
Jun 28, 2010
|
13.2 KB |
|
| |
INDIANAPOLIS and PARSIPPANY, N.J., June 28, 2010 /PRNewswire via COMTEX News Network/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company appreciate the availability of a "Clinical Alert" from the American College of Cardiology Foundation (ACCF) and American Heart Association (AHA) in response to the FDA's Boxed Warning about Plavix(R) (clopidogrel),...
|
|
Marcadia and Lilly Sign Development, License Agreement for Novel Glucagon Program in Severe Hypoglycemia
Jun 28, 2010
|
8.7 KB |
|
| |
INDIANAPOLIS, June 28, 2010 /PRNewswire via COMTEX News Network/ -- Marcadia Biotech, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the companies have signed a development and exclusive license agreement for Marcadia's short-acting glucagon program, covering glucagon analogs that may provide greater convenience and ease-of-use tha...
|
|
Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010
Jun 26, 2010
|
17.5 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced final results from a retrospective study including more than 260,000 patients that showed the risk of acute pancreatitis among initiators of BYETTA(R) (exenatide) injection was not in...
|
|
Type 2 Diabetes Patients With Long-Standing Disease Achieved Glycemic Control When BYETTA(R) Was Added to Lantus(R)
Jun 26, 2010
|
17.4 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA(R) (exenatide) injection added to Lantus(R) (insulin glargine), which showed patients with ty...
|
|
Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
Jun 26, 2010
|
17.8 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced results from a study comparing the effect of long-term treatment with either BYETTA(R) (exenatide) injection or Lantus(R) (insulin glargine) on overall beta-cell function. (Beta cells...
|
|
BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010
Jun 26, 2010
|
18.6 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results of an analysis of pooled safety data from three completed randomized controlled trials that showed the investigational product BYDUREON(TM) (exe...
|
|
Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes
Jun 22, 2010
|
12.0 KB |
|
| |
INDIANAPOLIS and BENTONVILLE, Ark., June 22, 2010 /PRNewswire via COMTEX News Network/ -- Walmart (NYSE: WMT) and Eli Lilly and Company (NYSE: LLY) announced today they're teaming up to provide an affordable insulin option for people with diabetes.
Beginning in mid-September, Lilly's Humulin(R) brand of insulin will be available in Walmart pharmac...
|
|
Lilly Declares Third-Quarter 2010 Dividend
Jun 21, 2010
|
6.3 KB |
|
| |
INDIANAPOLIS, June 21, 2010 /PRNewswire via COMTEX News Network/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2010 of $0.49 a share on outstanding common stock.
The dividend is payable September 10, 2010 to shareholders of record at the close of business on August 13, 2010.
Abou...
|
|
Kowa Pharmaceuticals America and Lilly Announce U.S. Availability of LIVALO
Jun 21, 2010
|
14.8 KB |
|
| |
MONTGOMERY, Ala. and INDIANAPOLIS, June 21, 2010 /PRNewswire via COMTEX News Network/ -- Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that LIVALO(R) (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug A...
|
|
DURATION-4 Study Results: BYDUREON Efficacy and Tolerability Profile Extended to Monotherapy Treatment
Jun 15, 2010
|
17.7 KB |
|
| |
SAN DIEGO, INDIANAPOLIS, and WALTHAM, Mass., June 15, 2010 /PRNewswire via COMTEX News Network/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from DURATION-4, the fourth in a series of studies designed to test the superiority of BYDUREON(TM) (exenatide ex...
|
|
|
